Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 20/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31605767 | 0.93 | PARG (0.54) | PARG | |
| SCHEMBL26688704 | 0.91 | PARG (0.51) | PARG | |
| SCHEMBL26688626 | 0.89 | PARG (0.49) | PARG | |
| SCHEMBL26688686 | 0.89 | PARG (0.55) | PARG | |
| SCHEMBL26688633 | 0.89 | PARG (0.57) | PARG | |
| SCHEMBL26688637 | 0.86 | PARG (0.47) | PARG | |
| SCHEMBL26688681 | 0.85 | PARG (0.46) | PARG | |
| SCHEMBL26688676 | 0.84 | PARG (0.44) | PARG | |
| SCHEMBL26688966 | 0.83 | PARG (0.47) | PARG | |
| SCHEMBL30643937 | 0.83 | PARG (0.53) | PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | claimed |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2024-10-24 | — | — | US | claimed |
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2024-10-24 | — | — | US | disclosed |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023224998-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374022-A1 | INHIBITORS OF PARG | PARG, PLG, SERPINB1 | PARG 1/4885 |
| US-12435092-B2 | Substituted imidazo[1,2-A]quinazolines as inhibitors of PARG | PARG, PLG, PTGIS | PARG 1/4885 |
| US-20240352018-A1 | SUBSTITUTED IMIDAZO[1,2-a]QUINAZOLINES AND IMIDAZO[1,2-a]PYRIDO[4,3-e]PYRIMIDINES AS INHIBITORS OF PARG | PARG, PLG, PARN | PARG 1/4885 |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | PARG, PTGIS, PLG | PARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.